[Quality of life following endocrine therapy for advanced prostate cancer: a comparative study between LH-RH agonist 1-month depot and 3-month depot].

What Was Tested

Researchers studied Goserelin in this randomized controlled trial publication.

There were few studies which reported the longitudinal quality of life (QOL) for Japanese men who received endocrine therapy for advanced or metastatic prostate cancer.

A pilot randomized trial was conducted to assess QOL and the incidence of hot flash following endocrine therapy using luteinizing hormone-releasing hormone (LH-RH) agonist goserelin acetate 1-month or 3-month depot alone in patients with advanced or metastatic prostate cancer.

Who Took Part

According to the abstract, 28 patients were involved.

PubMed indexes the participants as middle-aged adults and older adults, men only.

A baseline interview was conducted before treatment.

Follow-up interviews were conducted in person at scheduled study visits of 3, 6, 9 and 12 months after treatment.

How the Study Was Run

In design terms this was a randomized and pilot study.

Because people in this Goserelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

It is described as a pilot, a small early test of whether a larger Goserelin study would be practical.

Moreover, the researchers evaluated the incidence of hot flashes between the 1M and 3M depot.

What Was Measured

PubMed files the paper under topics including Antineoplastic Agents, Hormonal, Gonadotropin-Releasing Hormone, Goserelin, Hot Flashes, Neoplasm Staging, Pilot Projects and Prostatic Neoplasms.

What This Means in Plain Language

The paper is a randomized and pilot study of Goserelin in 28 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2008 (Nihon Hinyokika Gakkai zasshi. The japanese journal of urology), a journal based in Japan.

More context: the related Goserelin library page, all human trials.